Weikang Bio-Technology Launches New Good Health Package

HARBIN, China, Sept. 30 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company has recently launched its new Rongrun Good Health Package.  Total contribution to 2011 revenue and net income is expected to be $8.5 million and $3.1 million, respectively.  

"The Rongrun Good Health Package is our first bundled product which we believe offers consumers enhanced value and will accelerate the market acceptance of our new products," commented Dr. Ying Wang, Chairman & CEO of Weikang Bio-Technology Group Co., Inc.  "We intend to continue expanding our market share through regularly launching proprietary, high-quality, and high margin, new products that enhance consumers' health and overall wellbeing. We are also supporting our new products by continually building brand recognition through aggressive marketing campaigns and sales incentives."

The Rongrun Good Health Package includes three new therapeutics, Perilla Seed Soft Capsule, Yangshen Dan, Forest Frog Oil, combined with Kidney Boost Tonic.  All therapeutics have been approved by the State Food and Drug Administration (SFDA).  A brief description of the therapeutics are listed below:

Rongrun Good Health Package

• Perilla Seed Soft Capsule is primarily used to lower cholesterol, treat systems associated with dementia as well as improve memory.
• Kidney Boost Tonic is primarily used to improve the kidney function as well as enhance sexual performance.
• Yangshen Dan is primarily used to improve the body's microcirculation, or the body's circulation to the small arteries and veins, which enhances energy and sexual performance as well as impede cell deterioration.    
• Forest Frog Oil is primarily used to strengthen the body's immune system and enhance energy.  It is commonly used to treat symptoms associated with cardiovascular and cerebrovascular diseases as well as enhance sexual performance.  

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang.  For more information, please visit http://www.weikangbio.com/.

Safe Harbor Statement

This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.